清开灵注射液的不良反应

报道清开灵注射液致变态反应、急性喉阻塞、洋地黄毒性反应、急性左心衰竭等不良反应。     

奈达铂治疗恶性肿瘤研究进展

铂类化合物是治疗实体肿瘤的主要药物,自从1967年人们发现顺铂(cisplatin,DDP)有抗肿瘤活性以来,铂类金属抗肿瘤药的应用和研究得到了迅速的发展。奈达铂(nedaplatin,NDP;顺甘醇酸二氨合铂)是日本盐野义制药公司开发的第2代铂类抗肿瘤药,1995年在日本首次获准上市,目前,NDP主要用于头颈部肿瘤、肺癌、子宫癌、食道癌、膀胱癌、睾丸癌等,     

浅谈医源性胆道损伤的原因及防治

目的：探讨医源性胆道损伤的原因及防治。方法：回顾性分析我1995年6月-2012年12月收治的17例胆道损伤的诊治资料。结果：本院发生2例;外院转入15例。肝总管部分损伤8例,肝总管横断伤4例,胆总管部分损伤3例,胆总管横断1例,右肝管部分损伤1例。予不同处理,包括腹腔及胆管引流、胆总管修补,胆管对端吻合,胆（肝）管空肠Roux-en-Y吻合等。结论：除熟悉病理解剖关系外、经验和谨慎对预防胆囊切除致胆管损伤至关重要。对于胆道损伤应力争术中及时发现、早期正确处理。     

不同配伍比例麻黄-桂枝药对单煎与合煎化学成分对比分析

目的 分析不同配伍比例麻黄-桂枝药对单煎与合煎化学成分的差异性.方法 采集不同配伍比例麻黄-桂枝药对单煎与合煎样品的UPLC指纹图谱,采用SPSS 20.0对单煎与合煎样品指纹图谱共有峰的"峰面积/称样量"值进行比较.结果 不同配伍比例(2∶1、3∶2、1∶1、1∶2)的麻黄-桂枝药对单煎与合煎样品峰1、峰4的"峰面积...     

43例淋巴母细胞淋巴瘤患者临床特点及疗效分析

Objective To investigate the clinical features and treatment outcomes of different regimens in Chinese patients with lymphoblastic lymphoma(LBL). Methods Forty-three patients with LBL were retrospectively analysed, of which 30 were T-LBL, and 13 B-LBL. Results ①Most patients were young men with a median age of 21, and 63.0％ of the T-LBL patients had mediastinal masses. ② Treatment outcome could be assessed in 37 cases, of which the response rate (RR) was 81.1％ and complete remission (CR) rate was 67.6％. The RR and CR rates in patients treated with regimens for ALL (ALL-like group) and those treated with regimens for NHL(NHL-like group) were 94.4％ , 68.4％ and 83.3％ , 52.6％ , respectively. ③The estimated median overal survival(OS) and progression free survival (PFS) of hematopoietic stem cell transplantation (HSCT) group were significant longer than those of ALL-like group(P =0.018, P=0.025) and NHL-like group(P = 0. 016, P = 0. 011). The OS at 5 years in NHL-like group, ALL-like group and HSCT group were (14.4 ± 9.4) ％ , (20.2 ± 12.7) ％ and (79.5 ± 13.1) ％, respectively. Conclusion ①LBL is more common in young men, with less involvement of peripheral blood. Compared with B-LBL, T-LBL often has a mediastinal mass and serious cavity effusion. ② Intensive treatment regimens for ALL should be used in LBL. HSCT at CR1 can improve outcome obviously.     

后腹腔镜技术在泌尿外科中的应用

腹腔镜手术在腹部外科已广泛应用，在泌尿外科中可经腹腔和腹膜后经路。自1992年Gaurl首先报道后腹腔镜入路以来，经后腹腔镜技术在泌尿外科中得到了广泛开展。与经腹腔入路相比，经腹膜后入路相对安全，避免腹膜刺激和腹腔脏器损伤，从而具有更明显的优势。2003年1月。2008年4月，我们采用后腹腔镜技术在泌尿外科中应用58例，术后恢复好，随访2～62个月，无复发病例，效果满意，现报告如下。     

荧光原位杂交检测多发性骨髓瘤患者A13及其临床意义

目的 总结100例多发性骨髓瘤(MM)患者荧光原位杂交(FISH)检测△13(13q-/-13)阳性率及其临床意义.方法 对100例MM患者采用RB-1探针行FISH检测,并结合常规染色体(CC)结果分析其临床意义.结果 (1)△13 FISH检出率为19.0%,CC检出率为10.0%,差异未达统计学显著性(P=0.053).(2)单因素分析示FISH检测△13阳性率>50%、CC检测克隆性A13(C13A)、非超二倍体核型、FISH检测和CC检测双阳性、血β2-MG≥3.5 mg/L为不良预后因素.(3)多因素分析示FISH检测△13阳性率>50%和血β2-MG≥3.5 mg/L是独立预后因素.(4)根据上述两个独立预后因素,可将患者分为低、中、高危3组,两两比较总体生存时间(OS),差异均有统计学意义.结论 (1)FISH检测提高了初治MM遗传学异常的检出率.(2)预后分析示FISH检测△13阳性率>50%和血β2-MG水平为独立预后因素.     

谈新形势下医学生的医德教育

在新形势下，加强医学生的医德教育贯穿于医学教育的全过程，要在学习理论知识和专业技能的同时，强化医德教育，确立行为准则，建章立制，培养他们崇高的医德修养和良好的职业道德规范。同时，要努力营造良好的医德氛围，促使医德教育转化为自觉的医疗行为，以适应卫生行业改革和社会发展需要。     

43例淋巴母细胞淋巴瘤患者临床特点及疗效分析

Objective To investigate the clinical features and treatment outcomes of different regimens in Chinese patients with lymphoblastic lymphoma(LBL). Methods Forty-three patients with LBL were retrospectively analysed, of which 30 were T-LBL, and 13 B-LBL. Results ①Most patients were young men with a median age of 21, and 63.0％ of the T-LBL patients had mediastinal masses. ② Treatment outcome could be assessed in 37 cases, of which the response rate (RR) was 81.1％ and complete remission (CR) rate was 67.6％. The RR and CR rates in patients treated with regimens for ALL (ALL-like group) and those treated with regimens for NHL(NHL-like group) were 94.4％ , 68.4％ and 83.3％ , 52.6％ , respectively. ③The estimated median overal survival(OS) and progression free survival (PFS) of hematopoietic stem cell transplantation (HSCT) group were significant longer than those of ALL-like group(P =0.018, P=0.025) and NHL-like group(P = 0. 016, P = 0. 011). The OS at 5 years in NHL-like group, ALL-like group and HSCT group were (14.4 ± 9.4) ％ , (20.2 ± 12.7) ％ and (79.5 ± 13.1) ％, respectively. Conclusion ①LBL is more common in young men, with less involvement of peripheral blood. Compared with B-LBL, T-LBL often has a mediastinal mass and serious cavity effusion. ② Intensive treatment regimens for ALL should be used in LBL. HSCT at CR1 can improve outcome obviously.     

多发性骨髓瘤的细胞与分子生物学研究进展

多发性骨髓瘤是一种异质性疾病,近年来,其细胞与分子生物学尤其是分子遗传学方面的研究获得了一系列进展,对于我们更好地了解疾病、指导l临床分期及治疗都有重要的意义。本文对此方面的进展做一综述。